New drug cocktail shows promise for rare sinus cancer
NCT ID NCT07645846
First seen Jun 23, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for people with advanced sinonasal carcinoma, a rare cancer of the sinuses. Before surgery, patients receive a combination of two chemotherapy drugs (docetaxel and cisplatin) plus two immunotherapy drugs (sintilimab and ipilimumab). The goal is to shrink the tumor enough to improve surgical outcomes and possibly preserve facial structures. The study will enroll 23 participants and measure how many have a major response in their tumor tissue after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SINONASAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel, cisplatin, sintilimab, and ipilimumab
What this could lead to
If it works, this could point toward a more effective treatment for advanced sinonasal cancer that also helps preserve facial organs and functions.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The combination of chemotherapy and dual immunotherapy may cause significant side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.